OCTREOTIDE GH octreotide as acetate 50 micrograms/1 mL injection ampoule ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

octreotide gh octreotide as acetate 50 micrograms/1 ml injection ampoule

generic health pty ltd - octreotide, quantity: 50 microgram - injection, solution - excipient ingredients: mannitol; glycine; water for injections; dilute hydrochloric acid - for symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment. octreotide treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective. for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: carcinoid tumours with features of the carcinoid syndrome; vasoactive intestinal peptide secreting tumours (vipomas). octreotide is not an antitumour therapy and is not curative in these patients. for reduction of the incidence of complications following pancreatic surgery.

OCTREOTIDE GH octreotide as acetate 500 micrograms/1 mL injection ampoule ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

octreotide gh octreotide as acetate 500 micrograms/1 ml injection ampoule

generic health pty ltd - octreotide, quantity: 500 microgram - injection, solution - excipient ingredients: glycine; mannitol; dilute hydrochloric acid; water for injections - for symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment. octreotide treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective. for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: carcinoid tumours with features of the carcinoid syndrome; vasoactive intestinal peptide secreting tumours (vipomas). octreotide is not an antitumour therapy and is not curative in these patients. for reduction of the incidence of complications following pancreatic surgery.

OCTREOTIDE GH octreotide as acetate 100 micrograms/1 mL injection ampoule ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

octreotide gh octreotide as acetate 100 micrograms/1 ml injection ampoule

generic health pty ltd - octreotide, quantity: 100 microgram - injection, solution - excipient ingredients: glycine; dilute hydrochloric acid; mannitol; water for injections - for symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment. octreotide treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective. for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: carcinoid tumours with features of the carcinoid syndrome; vasoactive intestinal peptide secreting tumours (vipomas). octreotide is not an antitumour therapy and is not curative in these patients. for reduction of the incidence of complications following pancreatic surgery.

OCTREOTIDE DEPOT octreotide (as acetate) 20 mg modified release injection vial plus diluent prefilled syringe composite pack ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

octreotide depot octreotide (as acetate) 20 mg modified release injection vial plus diluent prefilled syringe composite pack

teva pharma australia pty ltd - octreotide, quantity: 20 mg - injection, modified release - excipient ingredients: polyglactin; mannitol - acromegaly for the symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment but who are adequately controlled on s.c. treatment with octreotide. octreotide depot is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,gastro-entero-pancreatic tumours for the relief of symptoms associated with the following functional tumours of the gastro-enteropancreatic endocrine system: ? carcinoid tumours with features of the carcinoid syndrome ? vasoactive intestinal peptide secreting tumours (vipomas) in patients who are adequately controlled on subcutaneous treatment with octreotide octreotide depot is not curative in these patients.,advanced neuroendocrine tumours of the midgut treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.

OCTREOTIDE DEPOT octreotide (as acetate) 30 mg modified release injection vial plus diluent prefilled syringe composite pack ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

octreotide depot octreotide (as acetate) 30 mg modified release injection vial plus diluent prefilled syringe composite pack

teva pharma australia pty ltd - octreotide, quantity: 30 mg - injection, modified release - excipient ingredients: polyglactin; mannitol - acromegaly for the symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment but who are adequately controlled on s.c. treatment with octreotide. octreotide depot is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,gastro-entero-pancreatic tumours for the relief of symptoms associated with the following functional tumours of the gastro-enteropancreatic endocrine system: ? carcinoid tumours with features of the carcinoid syndrome ? vasoactive intestinal peptide secreting tumours (vipomas) in patients who are adequately controlled on subcutaneous treatment with octreotide octreotide depot is not curative in these patients.,advanced neuroendocrine tumours of the midgut treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.

OCTREOTIDE DEPOT octreotide (as acetate) 10 mg modified release injection vial plus diluent prefilled syringe composite pack ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

octreotide depot octreotide (as acetate) 10 mg modified release injection vial plus diluent prefilled syringe composite pack

teva pharma australia pty ltd - octreotide, quantity: 10 mg - injection, modified release - excipient ingredients: polyglactin; mannitol - acromegaly for the symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment but who are adequately controlled on s.c. treatment with octreotide. octreotide depot is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,gastro-entero-pancreatic tumours for the relief of symptoms associated with the following functional tumours of the gastro-enteropancreatic endocrine system: ? carcinoid tumours with features of the carcinoid syndrome ? vasoactive intestinal peptide secreting tumours (vipomas) in patients who are adequately controlled on subcutaneous treatment with octreotide octreotide depot is not curative in these patients.,advanced neuroendocrine tumours of the midgut treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.

OCTREOTIDE SUN octreotide (as acetate) 50 microgram/1 mL solution for injection ampoule ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

octreotide sun octreotide (as acetate) 50 microgram/1 ml solution for injection ampoule

sun pharma anz pty ltd - octreotide -

OCTREOTIDE SUN octreotide (as acetate) 100 microgram/1 mL solution for injection ampoule ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

octreotide sun octreotide (as acetate) 100 microgram/1 ml solution for injection ampoule

sun pharma anz pty ltd - octreotide -

OCTREOTIDE SUN octreotide (as acetate) 500 microgram/1 mL solution for injection ampoule ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

octreotide sun octreotide (as acetate) 500 microgram/1 ml solution for injection ampoule

sun pharma anz pty ltd - octreotide -

OCTREOTIDE SUN octreotide (as acetate) 50 microgram/1 mL solution for injection ampoule ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

octreotide sun octreotide (as acetate) 50 microgram/1 ml solution for injection ampoule

sun pharma anz pty ltd - octreotide, quantity: 50 microgram - injection, solution - excipient ingredients: water for injections; sodium chloride; glacial acetic acid; sodium acetate trihydrate - for symptomatic control and reduction of growth hormone and igf-l plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment. octreotide treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: - carcinoid tumours with features of the carcinoid syndrome - vasoactive intestinal peptide secreting tumours [vipomas] octreotide is not curative in these patients.,for reduction of the incidence of complications following pancreatic surgery.